Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved ...

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers ...

ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

Laura Shawver, a director at ARS Pharmaceuticals Inc. (NASDAQ:SPRY), has sold 50,000 shares of common stock, according to a recent filing with the Securities and Exchange Commission. The shares were ...

EST ARS Pharmaceuticals (SPRY) files automatic mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) had its price target lifted by investment analysts at Leerink Partners from $26.00 to $27.00 in a report released on Monday,Benzinga reports.

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

These are not all of the possible side effects of neffy. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...